Novo Nordisk plots $1.3B in spending as it expands API production—and advances new oral meds

SourceFIERCE Pharma
Date Published02/04/2021
Author NameEric Sagonowsky
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Novo Nordisk
Parent companyNovo Nordisk Foundation
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
Capital investment ($):1300
Country(ies) from which reshored:Denmark
State(s) reshored to:NC
If relevant, work nearshored to:-
Industry(ies):Chemicals, pharmaceutical
Product(s) reshoredoral semaglutide drugs, oral biologic, Rybelsus
What domestic positive factors made reshoring more attractive?Infrastructure, Lead time/Time to market, Under-utilized capacity
Find Reshoring Articles